Mylan and Biocon announce acceptance for review its second biosimilar - Trastuzumab
By European Medicines Agency
Mylan N.V. and Biocon announced that the European Medicines Agency has accepted for review Mylan's Marketing Authorisation Application for a proposed biosimilar Trastuzumab, which is used to treat certain HER-2 positive breast and gastric cancers. This is the second biosimilar submission developed by the partnership that has been accepted for review in Europe.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content